![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BMS’s Opdivo Flops in Phase 3 Lung-Cancer Study
BMS’s Opdivo Flops in Phase 3 Lung-Cancer Study
August 11, 2016
Bristol-Myers Squibb revealed that Opdivo failed in a Phase 3 trial testing the drug’s efficacy as a monotherapy.
The trial failed to meet its endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer.
Beyond expressing disappointment in the results, company officials did not specify too what degree the drug failed.
Upcoming Events
-
21Oct